文献速递浆细胞疾病淋巴瘤

免疫调节药物通过Zap-70和cereblon依赖的双重途径激活NK细胞

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
PubMed 文献 · Leukemia · 2020-04-01

本研究探讨来那度胺和泊马度胺激活NK及T细胞杀伤功能的分子机制。研究发现IMiDs可直接结合并磷酸化激活Zap-70,且IMiDs诱导的颗粒酶B表达和NK细胞活性与Zap-70激活相关、可被Zap-70敲低抑制且不依赖CRBN。同时存在CRBN和IKZF3介导的第二条通路,可被CRBN或IKZF3敲低分别抑制或增强且不依赖Zap-70。

要点

  • IMiDs可直接结合T细胞中的Zap-70并促其酪氨酸残基磷酸化激活。
  • IMiDs诱导的颗粒酶B表达和NK细胞活性与Zap-70激活相关,Zap-70敲低可抑制且不依赖CRBN。
  • IMiDs还通过CRBN和IKZF3介导颗粒酶B表达和NK细胞毒性,该通路不依赖Zap-70。

核心结论

  • IMiDs可通过Zap-70介导的CRBN非依赖机制以及CRBN介导的Zap-70非依赖机制增强NK和T细胞对多发性骨髓瘤的细胞毒性。

研究设计与样本

  • 本研究为体外机制研究,探讨来那度胺和泊马度胺对T细胞和NK细胞中Zap-70及CRBN通路的激活作用。

主要发现

  • IMiDs可直接结合T细胞中的Zap-70并使其酪氨酸残基磷酸化。
  • IMiDs也可触发NK细胞中Zap-70的磷酸化。
  • IMiDs诱导的颗粒酶B表达和NK细胞活性增加与Zap-70激活相关,并被Zap-70敲低抑制,且不依赖CRBN。
  • IMiDs还通过CRBN和IKZF3介导颗粒酶B表达和NK细胞毒性,敲低CRBN或IKZF3分别抑制或增强该效应,且不依赖Zap-70。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide show remarkable antitumor activity in multiple myeloma (MM) via directly inhibiting MM-cell growth in the bone marrow (BM) microenvironment and promoting immune effector cell function. They are known to bind to the ubiquitin 3 ligase CRBN complex and thereby triggering degradation of IKZF1/3. In this study, we demonstrate that IMiDs also directly bind and activate zeta-chain-associated protein kinase-70 (Zap-70) via its tyrosine residue phosphorylation in T cells. IMiDs also triggered phosphorylation of Zap-70 in natural killer (NK) cells. Importantly, increased granzyme-B (GZM-B) expression and NK-cell activity triggered by IMiDs is associated with Zap-70 activation and inhibited by Zap-70 knockdown (KD), independent of CRBN. We also demonstrate a second mechanism whereby IMiDs trigger GZM-B and NK cytotoxicity which is CRBN and IKZF3 mediated, and inhibited or enhanced by KD of CRBN or IKZF3, respectively, independent of Zap-70. Our studies therefore show that IMiDs can enhance NK and T-cell cytotoxicity in (1) ZAP-70-mediated CRBN independent, as well as (2) CRBN-mediated ZAP-70 independent mechanisms; and provide the framework for developing novel therapeutics to activate Zap-70 and thereby enhance T and NK anti-MM cytotoxicity.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hideshima T, Ogiya D, Liu J, et al. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2020. PMID: 32238854. doi:10.1038/s41375-020-0809-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。